Selective GRP94 inhibitors and uses thereof
The disclosure relates to novel selective Grp94 inhibitors, compositions comprising an effective amount of such compounds, and methods to treat or prevent a condition, such as cancer, comprising administering to an animal in need thereof an effective amount of such compounds.
1 . A compound of the Formula (V):
or a pharmaceutically acceptable salt thereof, wherein:
(a) Y is —C(R Y ) 2 —, —S—, —NR—, —O—,
wherein each R Y is independently hydrogen, —OH, or halo;
(b) each of Z and Z 3 are independently —CH— or —N—;
(c) Z 2 is —N— or —CR 10 —, wherein R 10 is H or unsubstituted or substituted —(C 1 -C 6 )aliphatic;
(d) each of Z 4 , Z 5 , Z 6 , Z 7 and Z 8 are independently —C— or —N—, with the proviso that no three consecutive Z 4 through Z 8 are N;
(e) X 1 is —H, -halo, —N(R) 2 , —OR, —CN, or unsubstituted or substituted —(C 1 -C 6 )aliphatic;
(f) each of X 4 , X 5 , and X 6 are independently —H, -halo, —SR, —N(R) 2 , —OR, —CN, —NO 2 , —CN, —C(O)R, —C(O) 2 R, —S(O)R, —S(O) 2 R, —C(O)N(R) 2 , —SO 2 N(R) 2 , —OC(O)R, —N(R)C(O)R, —N(R)SO 2 R, —OC(O)N(R) 2 , unsubstituted or substituted —(C 1 -C 6 )aliphatic, or an unsubstituted or substituted group selected from (5- or 6-membered)aryl, (5- or 6-membered)arylalkyl, and (5- or 6-membered)heterocyclic aromatic or heterocyclic non-aromatic group; with the provisos that at least one of X 2 , X 4 and X 5 is —H and that X 2 is absent when Z 4 is —N—, X 3 is absent when Z 5 is —N—, X 4 is absent when Z 6 is —N— and X 5 is absent when Z 7 is —N—;
(g) each of X 2 and X 3 are independently selected from
(1) —H, -halo, —SR, —N(R) 2 , —OR, —CN, —NO 2 , —CN, —C(O)R, —C(O) 2 R, —S(O)R, —S(O) 2 R, —C(O)N(R) 2 , —SO 2 N(R) 2 , —OC(O)R, —N(R)C(O)R, —N(R)SO 2 R, —OC(O)N(R) 2 , unsubstituted or substituted —(C 1 -C 6 )aliphatic, or an unsubstituted or substituted group selected from (5- or 6-membered)aryl, (5- or 6-membered)arylalkyl, and (5- or 6-membered)heterocyclic aromatic or heterocyclic non-aromatic group; or
(2) X 2 and X 3 taken together form a fused benzo or fused (5- or 6-membered) heteroaryl that may be substituted with one or more R 8 groups;
(h) R 7 is —(C 1 -C 6 )aliphatic-N + —(R 2 )(R 3 )(R 4 ), —(C 1 -C 6 )aliphatic-N—R 3 R 4 , —(C 1 -C 6 )aliphatic- C(═O)N—R 3 R 4 , —(C 1 -C 6 )aliphatic-R 3 R 4 , —(C 1 -C 6 )aliphatic-R 2 R 3 R 4 , —(C 1 -C 6 )aliphatic-N—CR 2 R 3 R 4 , —(C 1 -C 6 )aliphatic-C(halo) 3 , —(C 1 -C 6 )aliphatic-alkynyl, —(C 1 -C 6 )aliphatic-(C 3 -C 8 )cycloalkyl, —(C 1 -C 6 )aliphatic-(C 3 -C 8 )heterocycloalkyl, —(C 1 -C 6 )aliphatic-phenyl, —(C 1 -C 6 )aliphatic-(5 or 6-membered)heteroaryl, —(C 1 -C 6 )aliphatic-cyano, with the proviso that when all of R 2 —R 4 are present the compound further comprises a pharmaceutically acceptable counter ion;
(i) R 2 and R 3 are independently hydrogen, —N(R) 2 , —CH 2 CH(OH)R 4 , —CH(OH)CH 2 R 4 , —CH 2 SO 2 NHR 4 , —CH 2 NHSO 2 R 4 , or unsubstituted or substituted —(C 1 -C 6 )aliphatic, or R 3 and R 4 form an unsubstituted or substituted 3- to 7-membered heterocyclic ring when taken together with the nitrogen to which they are attached;
(j) R 8 is —H, -halo, —SR, —N(R) 2 , —OR, —CN, —NO 2 , —CN, —C(O)R, —C(O) 2 R, —S(O)R, —S(O) 2 R, —C(O)N(R) 2 , —SO 2 N(R) 2 , —OC(O)R, —N(R)C(O)R, —N(R)SO 2 R, —OC(O)N(R) 2 , unsubstituted or substituted —(C 1 -C 6 )aliphatic, or an unsubstituted or substituted group selected from (5- or 6-membered)aryl, (5- or 6-membered)arylalkyl, and (5- or 6-membered)heterocyclic aromatic or heterocyclic non-aromatic group;
(k) R 4 is hydrogen, halogen, or unsubstituted or substituted —(C 1 -C 6 )aliphatic; and
(l) each R is independently hydrogen, unsubstituted C 1-6 aliphatic, or C 1-6 aliphatic substituted with halo, —OH, —CN, or —NH 2 ;
wherein each substituted group is substituted with one or more groups selected from halo, —N(R) 2 , —OR, —CN, oxo, unsubstituted C 1-6 aliphatic, or C 1-6 aliphatic substituted with halo, —OH, —CN, or —NH 2 .
2 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein:
(a) Y is —CH 2 —, —S—, —N—, —O—,
(b) each of Z 1 and Z 3 are independently —CH— or —N—;
(c) Z 2 is —CH—, —N—, or —CR 10 —, wherein R 10 is —(C 1 -C 6 )alkyl;
(d) each of Z 4 , Z 5 , Z 6 , Z 7 and Z 8 are independently —C— or —N—, with the proviso that no three consecutive Z 4 through Z 8 are N;
(e) X 1 is —H, -halo, —NH 2 , —CN, —(C 1 -C 6 )alkyl, —O(C 1 -C 6 )alkyl, —CH 2 OH, —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —OC(halo) 3 , —OCH(halo) 2 , or —OCH 2 (halo);
(f) each of X 4 , X 5 , and X 6 are independently —H, -halo, —NH 2 , —CN, —(C 1 -C 6 )alkyl, —O(C 1 -C 6 )alkyl, —CH 2 OH, —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —OC(halo) 3 , —OCH(halo) 2 , —OCH 2 (halo), pyridyl, furyl, thiophenyl, pyrrolyl, oxazolyl, imidazolyl, thiazolidinyl, thiadiazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, triazinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, 2,3-dihydrofuranyl, dihydropyridinyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, or tetrahydrothiopyranyl
(g) each of X 2 and X 3 are independently selected from
(1) —H, -halo, —NH 2 , —CN, —(C 1 -C 6 )alkyl, —O(C 1 -C 6 )alkyl, —CH 2 OH, —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —OC(halo) 3 , —OCH(halo) 2 , —OCH 2 (halo), pyridyl, furyl, thiophenyl, pyrrolyl, oxazolyl, imidazolyl, thiazolidinyl, thiadiazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, triazinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, 2,3-dihydrofuranyl, dihydropyridinyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, or tetrahydrothiopyranyl; and
(2) X 2 and X 3 taken together form a fused benzo or fused (5- or 6-membered) heteroaryl that may be substituted with one or more R 8 groups;
(h) R 7 is —(CH 2 ) m —N + —(R 2 )(R 3 )(R 4 ), —(CH 2 ) m —N—R 3 R 4 , —(CH 2 ) m —C(═O)N—R 3 R 4 , —(CH 2 ) m —C(halo) 3 , —(CH 2 ) m -alkynyl, (CH 2 ) m -alkynyl-CH 3 , (CH 2 ) m —(C 3 -C 8 )cycloalkyl, —(CH 2 ) m —(C 3 -C 8 )heterocycloalkyl, —(CH 2 ) m -phenyl, —(CH 2 ) m -(5 or 6-membered)heteroaryl, —(CH 2 ) m -cyano, where m is 1, 2, 3, 4 or 5 and where the cycloalkyl, heterocycle or phenyl is unsubstituted or substituted with one or more X 1 groups, with the proviso that when all of R 2 —R 4 are present the compound further comprises a pharmaceutically acceptable counter ion;
(i) R 2 and R 3 are independently hydrogen, methyl, ethyl, ethenyl, ethynyl, propyl, butyl, pentyl, hexyl, isopropyl, t-butyl, isobutyl, —C(halo) 3 , —C H (halo) 2 , —CH 2 (halo), —CH 2 C(halo) 3 , —CHCH(halo) 2 , CHCH 2 (halo), —CH 2 OH, —CH 2 CH 2 OH, —CH 2 C(CH 3 ) 2 OH, —CH 2 CH(CH 3 )OH, —C(CH 3 ) 2 CH 2 OH, or —CH(CH 3 )CH 2 OH, or R 2 and R 3 form an unsubstituted or substituted aziridine, azetidine, pyrrolidine or piperidine ring when taken together with the nitrogen to which they are attached;
(j) R 4 is hydrogen, methyl, ethyl, isopropyl, t-butyl, isobutyl, or —C(halo) 3 ; and
(k) R 8 is —H, -halo, —NH 2 , —CN, —(C 1 -C 6 )alkyl, —O(C 1 -C 6 )alkyl, —CH 2 OH, —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —OC(halo) 3 , —OCH(halo) 2 , or —OCH 2 (halo).
3 . The compound of claim 1 , having the following formula:
or a pharmaceutically acceptable salt thereof.
4 . The compound of claim 1 , having the following formula:
or a pharmaceutically acceptable salt thereof.
5 . The compound of claim 1 , having the following formula:
or a pharmaceutically acceptable salt thereof.
6 . The compound of claim 1 , having the following formula:
or a pharmaceutically acceptable salt thereof.
7 . The compound of claim 1 , having the following formula:
or a pharmaceutically acceptable salt thereof.
8 . The compound of claim 1 , having the following formula:
or a pharmaceutically acceptable salt thereof.
9 . The compound of claim 1 , having the following formula:
or a pharmaceutically acceptable salt thereof.
10 . A compound having the following formula:
or, or a pharmaceutically acceptable salt thereof.
11 . A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable excipient.
12 . A pharmaceutical composition comprising a compound of claim 3 , and a pharmaceutically acceptable excipient.
13 . A pharmaceutical composition comprising a compound of claim 6 , and a pharmaceutically acceptable excipient.
14 . A pharmaceutical composition comprising a compound of claim 7 , and a pharmaceutically acceptable excipient.
15 . A pharmaceutical composition comprising a compound of claim 10 , and a pharmaceutically acceptable excipient.
16 . A method of treating cancer, autoimmune diseases, inflammatory diseases, neurodegenerative diseases, rheumatoid arthritis, or diabetes in a patient comprising administering a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
17 . A method of treating cancer, autoimmune diseases, inflammatory diseases, neurodegenerative diseases, rheumatoid arthritis, or diabetes in a patient, comprising administering a therapeutically effective amount of a compound of claim 3 , or a pharmaceutically acceptable salt thereof.
18 . A method of treating cancer, autoimmune diseases, inflammatory diseases, neurodegenerative diseases, rheumatoid arthritis, or diabetes in a patient, comprising administering a therapeutically effective amount of a compound of claim 7 , or a pharmaceutically acceptable salt thereof.
19 . A method of treating cancer, autoimmune diseases, inflammatory diseases, neurodegenerative diseases, rheumatoid arthritis, or diabetes in a patient comprising administering a therapeutically effective amount of a compound of claim 7 , or a pharmaceutically acceptable salt thereof.
20 . A method of treating cancer, autoimmune diseases, inflammatory diseases, neurodegenerative diseases, rheumatoid arthritis, or diabetes in a patient, comprising administering a therapeutically effective amount of a compound of claim 10 , or a pharmaceutically acceptable salt thereof.